CASI Pharmaceuticals ( (CASI) ) has issued an update.
CASI Pharmaceuticals reported its fourth quarter and full-year 2024 financial results, highlighting a strategic pivot towards developing CID-103 for organ transplant rejection and autoimmune diseases. The company achieved significant milestones, including the first dosing of a patient with CID-103 in January 2025 and ongoing efforts to resolve an FDA clinical hold. Despite a 94% increase in fourth-quarter revenue to $13.4 million, full-year revenue decreased by 16% due to intensified competition. CASI’s financial strategy includes prudent capital allocation to ensure long-term value creation for patients and shareholders.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and globally. The company specializes in hematology oncology therapeutics, organ transplant rejection, autoimmune diseases, and other unmet medical needs. CASI leverages its China-based regulatory and commercial expertise along with global drug development capabilities to establish a leadership position in the Greater China market.
YTD Price Performance: -27.95%
Average Trading Volume: 15,666
Technical Sentiment Signal: Strong Buy
Current Market Cap: $28.78M
Find detailed analytics on CASI stock on TipRanks’ Stock Analysis page.